Interleukin-2 or Observation Following Radiation Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma

Total Body Irradiation, Etoposide, Cyclophosphamide and Autologous Peripheral Blood Stem Cell Transplantation Followed by Randomization to Therapy With Interleukin-2 Versus Observation for Patients With Non-Hodgkin's Lymphoma

Randomized phase III trial to compare the effectiveness of interleukin-2 with that of observation following radiation therapy, combination chemotherapy, and peripheral stem cell transplantation in treating patients who have refractory or relapsed non-Hodgkin's lymphoma. Interleukin-2 may stimulate a person's white blood cells to kill non-Hodgkin's lymphoma cells. Giving interleukin-2 after radiation therapy, chemotherapy, and peripheral stem cell transplantation may kill more cancer cells

Study Overview

• Status: Completed
• Conditions: Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma
• Intervention / Treatment: Drug: cyclophosphamide; Drug: etoposide; Radiation: radiation therapy; Biological: aldesleukin; Procedure: peripheral blood stem cell transplantation; Biological: filgrastim; Procedure: bone marrow ablation with stem cell support

Detailed Description

PRIMARY OBJECTIVES:

I. To compare the survival and disease-free survival of patients with non-Hodgkin's lymphoma treated with post-transplant therapy with interleukin-2 (IL-2) or no further treatment. Transplant therapy is total body irradiation (TBI), high-dose etoposide, cyclophosphamide and peripheral blood stem cell transplant (PBSCT).

II. To assess the frequency and severity of toxicity associated with post-transplant IL-2 therapy.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to disease grade (low vs intermediate vs high), chemosensitive disease (yes vs no), partial or complete response after initial induction chemotherapy (yes vs no), and performance status (0-1 vs 2).

Part I: Autologous peripheral blood stem cells (PBSC) are harvested before study entry. Patients undergo total body irradiation twice a day on days -8 to -5, high-dose etoposide IV over 4 hours on day -4, and cyclophosphamide IV over 1 hour on day -2. PBSC are reinfused on day 0 and then filgrastim (G-CSF) may be administered subcutaneously or IV on days 0-21.

Part II: Within 28-80 days after PBSC transplantation and after recovery from any toxic effects, patients with no active recurrent or progressive disease are randomized to 1 of 2 treatment arms.

Arm I: Patients receive interleukin-2 IV continuously on days 1-4 and 9-18.

Arm II: Patients undergo observation only.

Patients are followed every 3 months for 1 year, every 6 months for 3 years, and then annually thereafter.

PROJECTED ACCRUAL: Approximately 275 patients will be accrued for this study within 3.5-5.9 years.

• Study Type: Interventional
• Enrollment (Actual): 206
• Phase: Phase 3

Contacts and Locations

Study Locations

• United States
  • Texas
    • San Antonio, Texas, United States, 78245
      • Southwest Oncology Group

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years to 60 years (Child, Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• REGISTRATION # 1
• All patients must have biopsy proven diagnosis of low, intermediate or high grade malignant non-Hodgkin's lymphoma; transformed lymphomas are eligible
• Patients with histologic diagnosis of working formulation A (malignant lymphoma small lymphocytic) or working formulation I (malignant lymphoma, lymphoblastic) are not eligible
• Patients must have relapsed after achieving a complete or partial response to prior therapy, or have never responded to prior therapy
• Patients must have debulking (salvage) chemotherapy to determine if the disease is sensitive to chemotherapy; the sole exception to this requirement is for patients with intermediate or high grade lymphoma (working formulation D - H or J) whose disease did not respond to, or progressed during, INITIAL chemotherapy

• Prior therapy is required; concurrent therapy is NOT permitted

  • Patients with low grade lymphoma (working formulation B or C) must have received at least two prior chemotherapy regimens; if the patient has had one or more CR, then the most recent CR must have been less than one year in duration
  • Patients with intermediate or high grade non-Hodgkin's lymphoma (working formulation D - H or J) must have received at least one prior chemotherapy regimen
  • NOTE: Debulking chemotherapy given only to determine sensitivity is not considered in the calculation of number of prior regimens
• Patients must have a bone marrow aspirate and biopsy obtained within 42 days of stem cell collection or within 42 days prior to registration
• Patients with a history of seizures or central nervous system involvement by lymphoma are NOT eligible
• Only patients with a normal cardiac history and physical exam or in lieu of this, an institutionally normal ejection fraction as measured by either ECHO or MUGA scan are eligible; specifically, there should be: no EKG evidence of active cardiac disease (i.e., arrhythmias, ischemia), no history of congestive heart failure (CHF), no history of myocardial infarction or ischemia, no history of arrhythmia (other than bradycardia treated by pacing), no current cardiac medications for the control of CHF or arrhythmias, no S3 gallop rhythm, or peripheral edema, and no chest X-ray findings compatible with CHF; EKG must be performed within 42 days prior to registration
• All patients must have a pretreatment serum creatinine of =< 1.5 times the institutional upper limit of normal measured after completion of prior therapy and within 28 days prior to registration
• Patients must have adequate pulmonary function as measured by a DLCO >= 65% of predicted or FEV1 >= 65% of predicted measured after completion of prior therapy and within 120 days prior to registration
• Patients must have adequate hepatic function as measured by a bilirubin of =< 1.5 x the institutional upper limit of normal and SGOT or SGPT =< 2 x the institutional upper limit of normal, measured after completion of prior therapy and within 28 days prior to registration
• Patients who have undergone previous bone marrow transplantation or autologous peripheral blood stem cell transplantation are NOT eligible
• Patients who have undergone previous therapy with interleukin-2 are NOT eligible
• Patients must have recovered from the nadir resulting from the last cancer therapy; this will generally be at least four weeks from prior radiation or chemotherapy, and six weeks from nitrosoureas
• Patients must have a Southwest Oncology Group performance status of 0 or 1
• Patients must have a CT scan of the chest, abdomen and pelvis performed within 28 days prior to registration and at least 21 days after the completion of prior chemotherapy (excluding mobilization therapy)
• Patients must have LDH performed within 28 days prior to registration and at least 21 days after completion of prior chemotherapy (excluding mobilization therapy)
• Patients must have undergone an adequate collection of peripheral blood stem cells (PBSC) according to accepted procedures at each individual institution
• Patients with known allergy to etoposide or a history of grade 3 hemorrhagic cystitis with cyclophosphamide are not eligible
• Patients who have received prior involved field irradiation prohibiting the use of TBI are not eligible
• Patients must be negative for antibody to HIV and this test must have been performed within 42 days prior to registration; patients must not have an autoimmune disease or have had a prior allogeneic (from someone else) organ or tissue transplant
• If day 28 or 42 falls on a weekend or holiday, the limit may be extended to the next working day; in calculating days of tests and measurements, the day a test or measurement is done is considered day 0; therefore, if a test is done on a Monday, the Monday four weeks later would be considered day 28; this allows for efficient patient scheduling without exceeding the guidelines
• No prior malignancy is allowed except for adequately treated basal cell (or squamous cell) skin cancer, in situ cervical cancer or other cancer for which the patient has been disease-free for five years
• Pregnant or nursing women may not participate; women or men of reproductive potential may not participate unless they have agreed to use an effective contraceptive method
• Patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines
• At the time of patient registration, the treating institution's name and ID number must be provided to the statistical center in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered into the database
• REGISTRATION # 2 (RANDOMIZATION)
• Patients who are less than 28 days or more than 80 days after PBSCT will not be registered for randomization
• Patients known to be ineligible for registration step #1 may not be registered to registration step #2
• Restaging radiographic studies are not required between PBSCT and registration #2 (randomization), however, patients with known active recurrent or progressive disease are not eligible for randomization
• ANC > 500 mm^3
• Platelet count supportable to > 20,000/mm^3 with no more than one transfusion per day
• The patient must be free of active bacterial, fungal or viral infection, afebrile, off antibiotics, antifungal and antiviral agents (with the exception of prophylactic therapy) for three consecutive days
• Bilirubin =< 2 times the institutional upper limit of normal; test must be completed within 7 days prior to registration
• SGOT or SGPT =< 2 times the institutional upper limit of normal; test must be completed within 7 days prior to registration
• Alkaline phosphatase =< 2 times the institutional upper limit of normal; test must be completed within 7 days prior to registration
• Creatinine =< 1.5 times the institutional upper limit of normal; test must be completed within 7 days prior to registration
• The patient must have =< grade 1 cardiac, pulmonary, CNS, renal, hepatic, GI toxicity and < grade 3 mucosal toxicity according to the Southwest Oncology Group Toxicity Criteria
• The patient must have received no amphotericin B, corticosteroids, pentoxifylline, or growth factors for at least 72 hours prior to registration
• The patient must have a current Southwest Oncology Group performance status of 0-2
• Patients must have an EKG with no active cardiac disease and a chest x-ray with no active pulmonary disease; these tests must be completed within 7 days prior to registration
• Patients must not have an autoimmune disease or have had a prior allogeneic (from someone else) organ or tissue transplant

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Arm I (autologous PBSCT, TBI, etoposide, cyclophosphamide); Part I: Autologous PBSC are harvested before study entry. Patients undergo total body irradiation twice a day on days -8 to -5, high-dose etoposide IV over 4 hours on day -4, and cyclophosphamide IV over 1 hour on day -2. PBSC are reinfused on day 0 and then G-CSF may be administered subcutaneously or IV on days 0-21. Part II: Within 28-80 days after PBSC transplantation and after recovery from any toxic effects, patients with no active recurrent or progressive disease are randomized to 1 of 2 treatment arms. Patients receive interleukin-2 IV continuously on days 1-4 and 9-18.	Drug: cyclophosphamide; Given IV; Other Names: Cytoxan; Endoxan; CPM; CTX; Endoxana; Drug: etoposide; Given IV; Other Names: EPEG; VP-16; VP-16-213; Radiation: radiation therapy; Undergo radiation therapy; Other Names: irradiation; radiotherapy; therapy, radiation; Biological: aldesleukin; Given IV; Other Names: Proleukin; IL-2; recombinant human interleukin-2; recombinant interleukin-2; Procedure: peripheral blood stem cell transplantation; Undergo autologous peripheral blood stem cell transplant; Other Names: PBPC transplantation; PBSC transplantation; peripheral blood progenitor cell transplantation; transplantation, peripheral blood stem cell; Biological: filgrastim; Given SC or IV; Other Names: G-CSF; Neupogen; Procedure: bone marrow ablation with stem cell support; Undergo bone marrow ablation with stem cell support
No Intervention: Arm II (observation only); Patients undergo observation only.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Overall survival	Up to 13 years
Disease-free survival	Up to 13 years
Frequency and severity of toxicity associated with post-transplant aldesleukin therapy	Up to 13 years

Collaborators and Investigators

• Sponsor: National Cancer Institute (NCI)
• Investigators: Principal Investigator: John Thompson, Southwest Oncology Group

Publications and helpful links

General Publications

• Thompson JA, Fisher RI, Leblanc M, Forman SJ, Press OW, Unger JM, Nademanee AP, Stiff PJ, Petersdorf SH, Fefer A. Total body irradiation, etoposide, cyclophosphamide, and autologous peripheral blood stem-cell transplantation followed by randomization to therapy with interleukin-2 versus observation for patients with non-Hodgkin lymphoma: results of a phase 3 randomized trial by the Southwest Oncology Group (SWOG 9438). Blood. 2008 Apr 15;111(8):4048-54. doi: 10.1182/blood-2007-09-111708. Epub 2008 Feb 6.

Study record dates

Study Major Dates

• Study Start: May 1, 1995
• Primary Completion (Actual): November 1, 2006

Study Registration Dates

• First Submitted: November 1, 1999
• First Submitted That Met QC Criteria: January 26, 2003
• First Posted (Estimate): January 27, 2003

Study Record Updates

• Last Update Posted (Estimate): February 28, 2013
• Last Update Submitted That Met QC Criteria: February 27, 2013
• Last Verified: February 1, 2013

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Virus Diseases; Infections; Immune System Diseases; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Disease Attributes; DNA Virus Infections; Tumor Virus Infections; Epstein-Barr Virus Infections; Herpesviridae Infections; Lymphoma, B-Cell; Lymphoma; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Recurrence; Lymphoma, Non-Hodgkin; Burkitt Lymphoma; Lymphoma, Large-Cell, Immunoblastic; Plasmablastic Lymphoma; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Anti-Infective Agents; Peripheral Nervous System Agents; Antiviral Agents; Enzyme Inhibitors; Anti-HIV Agents; Anti-Retroviral Agents; Analgesics; Sensory System Agents; Analgesics, Non-Narcotic; Antirheumatic Agents; Antineoplastic Agents; Immunosuppressive Agents; Immunologic Factors; Antineoplastic Agents, Alkylating; Alkylating Agents; Myeloablative Agonists; Antineoplastic Agents, Phytogenic; Topoisomerase II Inhibitors; Topoisomerase Inhibitors; Aldesleukin; Cyclophosphamide; Etoposide; Etoposide phosphate; Interleukin-2
• Other Study ID Numbers: NCI-2012-03072; U10CA032102 (U.S. NIH Grant/Contract); SWOG-9438; CDR0000064175 (Registry Identifier: PDQ (Physician Data Query))